Testicular Embryonal Carcinoma
NCI Definition: A malignant germ cell neoplasm arising from the testis. It is composed of primitive epithelial cells arranged in solid, papillary, and glandular configurations. Most patients present with a testicular mass, which may be associated with pain. More than half of the patients have metastatic disease at diagnosis. The form of treatment following radical orchiectomy is stage dependent. 
Testicular embryonal carcinomas most frequently harbor alterations in CDKN1B, ETV6, CCND2, RAD52, and KRAS .
CDKN1B Amplification, CCND2 Amplification, ETV6 Amplification, RAD52 Amplification, and KRAS Amplification are the most common alterations in testicular embryonal carcinoma .
There are 6 clinical trials for testicular embryonal carcinoma, of which 6 are open and 0 are completed or closed. Of the trials that contain testicular embryonal carcinoma as an inclusion criterion, 2 are phase 1 (2 open) and 4 are phase 2 (4 open).
Ipilimumab, nivolumab, and aldesleukin are the most common interventions in testicular embryonal carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.